Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


Unique-region phosphorylation targets LynA for rapid degradation, tuning its expression and signaling in myeloid cells.

Brian BF 4th, Jolicoeur AS, Guerrero CR, Nunez MG, Sychev ZE, Hegre SA, Sætrom P, Habib N, Drake JM, Schwertfeger KL, Freedman TS.

Elife. 2019 Jul 8;8. pii: e46043. doi: 10.7554/eLife.46043.


JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors.

Irey EA, Lassiter CM, Brady NJ, Chuntova P, Wang Y, Knutson TP, Henzler C, Chaffee TS, Vogel RI, Nelson AC, Farrar MA, Schwertfeger KL.

Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12442-12451. doi: 10.1073/pnas.1816410116. Epub 2019 May 30.


Inflammation as a Target in Cancer Therapy.

Leon-Cabrera S, Schwertfeger KL, Terrazas LI.

Mediators Inflamm. 2019 Mar 7;2019:1971698. doi: 10.1155/2019/1971698. eCollection 2019. No abstract available.


Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression.

Nelson AC, Machado HL, Schwertfeger KL.

J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):207-221. doi: 10.1007/s10911-018-9409-z. Epub 2018 Aug 31. Review.


Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.

Regan Anderson TM, Ma S, Perez Kerkvliet C, Peng Y, Helle TM, Krutilina RI, Raj GV, Cidlowski JA, Ostrander JH, Schwertfeger KL, Seagroves TN, Lange CA.

Mol Cancer Res. 2018 Nov;16(11):1761-1772. doi: 10.1158/1541-7786.MCR-18-0410. Epub 2018 Jul 10.


Distant Relations: Macrophage Functions in the Metastatic Niche.

Doak GR, Schwertfeger KL, Wood DK.

Trends Cancer. 2018 Jun;4(6):445-459. doi: 10.1016/j.trecan.2018.03.011. Epub 2018 May 3. Review.


Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes.

Truong TH, Hu H, Temiz NA, Hagen KM, Girard BJ, Brady NJ, Schwertfeger KL, Lange CA, Ostrander JH.

Mol Cancer Res. 2018 Apr;16(4):707-719. doi: 10.1158/1541-7786.MCR-17-0598. Epub 2018 Jan 18.


Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions.

Aukes K, Forsman C, Brady NJ, Astleford K, Blixt N, Sachdev D, Jensen ED, Mansky KC, Schwertfeger KL.

PLoS One. 2017 Oct 2;12(10):e0185736. doi: 10.1371/journal.pone.0185736. eCollection 2017.


STAT5 deletion in macrophages alters ductal elongation and branching during mammary gland development.

Brady NJ, Farrar MA, Schwertfeger KL.

Dev Biol. 2017 Aug 1;428(1):232-244. doi: 10.1016/j.ydbio.2017.06.007. Epub 2017 Jun 9.


Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.

Knutson TP, Truong TH, Ma S, Brady NJ, Sullivan ME, Raj G, Schwertfeger KL, Lange CA.

J Hematol Oncol. 2017 Apr 17;10(1):89. doi: 10.1186/s13045-017-0462-7.


Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ϵ and Inflammatory Cross-talk with Macrophages.

Girard BJ, Knutson TP, Kuker B, McDowell L, Schwertfeger KL, Ostrander JH.

J Biol Chem. 2017 Jan 6;292(1):339-350. doi: 10.1074/jbc.M116.739847. Epub 2016 Nov 23.


ADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation.

Bohrer LR, Chaffee TS, Chuntova P, Brady NJ, Witschen PM, Kemp SE, Nelson AC, Walcheck B, Schwertfeger KL.

Genes Cancer. 2016 Jul;7(7-8):240-253. doi: 10.18632/genesandcancer.115.


Macrophages: Regulators of the Inflammatory Microenvironment during Mammary Gland Development and Breast Cancer.

Brady NJ, Chuntova P, Schwertfeger KL.

Mediators Inflamm. 2016;2016:4549676. doi: 10.1155/2016/4549676. Epub 2016 Jan 17. Review.


Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Brincks EL, Kucaba TA, James BR, Murphy KA, Schwertfeger KL, Sangwan V, Banerjee S, Saluja AK, Griffith TS.

FEBS J. 2015 Dec;282(24):4747-4765. doi: 10.1111/febs.13532. Epub 2015 Oct 18.


Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.

Farooqui M, Bohrer LR, Brady NJ, Chuntova P, Kemp SE, Wardwell CT, Nelson AC, Schwertfeger KL.

Mol Cancer. 2015 Jul 29;14:138. doi: 10.1186/s12943-015-0408-z.


Hyaluronan, Inflammation, and Breast Cancer Progression.

Schwertfeger KL, Cowman MK, Telmer PG, Turley EA, McCarthy JB.

Front Immunol. 2015 Jun 8;6:236. doi: 10.3389/fimmu.2015.00236. eCollection 2015. Review.


The Content and Size of Hyaluronan in Biological Fluids and Tissues.

Cowman MK, Lee HG, Schwertfeger KL, McCarthy JB, Turley EA.

Front Immunol. 2015 Jun 2;6:261. doi: 10.3389/fimmu.2015.00261. eCollection 2015. Review.


eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells.

Avdulov S, Herrera J, Smith K, Peterson M, Gomez-Garcia JR, Beadnell TC, Schwertfeger KL, Benyumov AO, Manivel JC, Li S, Bielinsky AK, Yee D, Bitterman PB, Polunovsky VA.

Cancer Res. 2015 Feb 15;75(4):687-97. doi: 10.1158/0008-5472.CAN-14-2571. Epub 2014 Dec 18.


PVT1 dependence in cancer with MYC copy-number increase.

Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell TC, Essig J, Otto GM, O'Sullivan MG, Largaespada DA, Schwertfeger KL, Marahrens Y, Kawakami Y, Bagchi A.

Nature. 2014 Aug 7;512(7512):82-6. doi: 10.1038/nature13311. Epub 2014 Jun 22.


Building bridges toward invasion: tumor promoter treatment induces a novel protein kinase C-dependent phenotype in MCF10A mammary cell acini.

Klos KS, Warmka JK, Drachenberg DM, Chang L, Luxton GW, Leung CT, Schwertfeger KL, Wattenberg EV.

PLoS One. 2014 Mar 5;9(3):e90722. doi: 10.1371/journal.pone.0090722. eCollection 2014.


Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation.

Bohrer LR, Chuntova P, Bade LK, Beadnell TC, Leon RP, Brady NJ, Ryu Y, Goldberg JE, Schmechel SC, Koopmeiners JS, McCarthy JB, Schwertfeger KL.

Cancer Res. 2014 Jan 1;74(1):374-86. doi: 10.1158/0008-5472.CAN-13-2469. Epub 2013 Nov 6.


The FGF/FGFR axis as a therapeutic target in breast cancer.

Brady N, Chuntova P, Bade LK, Schwertfeger KL.

Expert Rev Endocrinol Metab. 2013 Jul;8(4):391-402. doi: 10.1586/17446651.2013.811910.


BMP-binding protein twisted gastrulation is required in mammary gland epithelium for normal ductal elongation and myoepithelial compartmentalization.

Forsman CL, Ng BC, Heinze RK, Kuo C, Sergi C, Gopalakrishnan R, Yee D, Graf D, Schwertfeger KL, Petryk A.

Dev Biol. 2013 Jan 1;373(1):95-106. doi: 10.1016/j.ydbio.2012.10.007. Epub 2012 Oct 24.


Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner.

Reed JR, Stone MD, Beadnell TC, Ryu Y, Griffin TJ, Schwertfeger KL.

PLoS One. 2012;7(9):e45877. doi: 10.1371/journal.pone.0045877. Epub 2012 Sep 24.


Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner.

Bohrer LR, Schwertfeger KL.

Mol Cancer Res. 2012 Oct;10(10):1294-305. doi: 10.1158/1541-7786.MCR-12-0275. Epub 2012 Aug 14.


Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.

Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL, Schwertfeger KL, Lange CA.

Breast Cancer Res. 2011 Sep 17;13(5):R89. doi: 10.1186/bcr2946.


Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.

Bade LK, Goldberg JE, Dehut HA, Hall MK, Schwertfeger KL.

J Cell Sci. 2011 Sep 15;124(Pt 18):3106-17. doi: 10.1242/jcs.082651. Epub 2011 Aug 24.


Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications.

Dressing GE, Goldberg JE, Charles NJ, Schwertfeger KL, Lange CA.

Steroids. 2011 Jan;76(1-2):11-7. doi: 10.1016/j.steroids.2010.09.006. Epub 2010 Sep 24. Review.


Immune cell location and function during post-natal mammary gland development.

Reed JR, Schwertfeger KL.

J Mammary Gland Biol Neoplasia. 2010 Sep;15(3):329-39. doi: 10.1007/s10911-010-9188-7. Epub 2010 Aug 24. Review.


Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics.

Goldberg JE, Schwertfeger KL.

Curr Drug Targets. 2010 Sep;11(9):1133-46. Review.


Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer.

Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, Lloyd RE, Rosen JM.

Cancer Res. 2010 Jun 15;70(12):4868-79. doi: 10.1158/0008-5472.CAN-09-4404. Epub 2010 May 25.


Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands.

Schwertfeger KL.

Curr Drug Targets. 2009 Jul;10(7):632-44. Review.


Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis.

Reed JR, Leon RP, Hall MK, Schwertfeger KL.

Breast Cancer Res. 2009;11(2):R21. doi: 10.1186/bcr2246. Epub 2009 Apr 24.


Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition.

Xian W, Schwertfeger KL, Rosen JM.

Mol Endocrinol. 2007 Apr;21(4):987-1000. Epub 2007 Feb 6.


Mammary gland macrophages: pleiotropic functions in mammary development.

Schwertfeger KL, Rosen JM, Cohen DA.

J Mammary Gland Biol Neoplasia. 2006 Oct;11(3-4):229-38. Review.


MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells.

Limesand KH, Schwertfeger KL, Anderson SM.

Mol Cell Biol. 2006 Dec;26(23):8840-56. Epub 2006 Sep 18.


A critical role for the inflammatory response in a mouse model of preneoplastic progression.

Schwertfeger KL, Xian W, Kaplan AM, Burnett SH, Cohen DA, Rosen JM.

Cancer Res. 2006 Jun 1;66(11):5676-85.


Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model.

Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM.

J Cell Biol. 2005 Nov 21;171(4):663-73.


Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation.

Schwertfeger KL, McManaman JL, Palmer CA, Neville MC, Anderson SM.

J Lipid Res. 2003 Jun;44(6):1100-12. Epub 2003 Apr 16.


Mammary gland involution is delayed by activated Akt in transgenic mice.

Schwertfeger KL, Richert MM, Anderson SM.

Mol Endocrinol. 2001 Jun;15(6):867-81.


An atlas of mouse mammary gland development.

Richert MM, Schwertfeger KL, Ryder JW, Anderson SM.

J Mammary Gland Biol Neoplasia. 2000 Apr;5(2):227-41. Review.


Prolactin stimulates activation of c-jun N-terminal kinase (JNK).

Schwertfeger KL, Hunter S, Heasley LE, Levresse V, Leon RP, DeGregori J, Anderson SM.

Mol Endocrinol. 2000 Oct;14(10):1592-602.


Supplemental Content

Loading ...
Support Center